New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
16:17 EDTCERUCerulean reports Q2 EPS (44c), consensus (36c)
Reports Q2 revenue $33K. As of June 30, Cerulean had cash and cash equivalents of $64.3M. Cerulean estimates that its current cash and cash equivalents will allow it to fund several ongoing single-arm clinical trials of CRLX101, an ongoing randomized Phase 2 clinical trial of CRLX101, and a planned Phase 1 trial of CRLX301. CEO Oliver Fetzer said, "We anticipate announcing data from two ongoing single-arm CRLX101 trials in the first quarter of 2015, data from an ongoing randomized CRLX101 trial by the end of 2015, and data from a planned Phase 1 CRLX301 trial by the end of 2015."
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 18, 2015
20:19 EDTCERUCerulean participates in lunch meeting with Philadelphia Securities Association
Luncheon meeting with management being held in Philadelphia on April 21 at 11:30 am hosted by Philadelphia Securities Association.
April 13, 2015
07:11 EDTCERUCerulean says publication shows CRLX101 targets breast cancer stem cells
Cerulean Pharma announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Cerulean’s lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models. The results of the study demonstrate that CRLX101, a dual topoisomerase-1 and HIF-1α inhibitor, blocks the HIF-1α mediated increase in cancer stem cells induced by Avastin in a triple-negative breast cancer xenograft mouse model. The up-regulation of HIF-1α by Avastin is believed to be a mechanism of resistance to anti-angiogenic therapy. The combined effects of CRLX101 plus Avastin on cancer stem cells and bulk tumor cells resulted in significant tumor shrinkage and delayed recurrence in this model. The manuscript posits that these data provide a compelling rationale for combining CRLX101 with angiogenic agents in patients with cancer where HIF-1α mediated increases in cancer stem cells may play a role in chemoresistance. The article, “CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to anti-angiogenic therapy in mouse models of breast cancer” by Conley, et al, was published in the April 2015 issue of Breast Cancer Research and Treatment.
April 7, 2015
06:07 EDTCERUCerulean 5.8M share Secondary priced at $6.00
Subscribe for More Information
April 6, 2015
06:20 EDTCERUCerulean files to sell $35M in common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use